Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Background: Immune checkpoint inhibitors confer significant clinical benefit by bolstering immune-system activity, however, they also produce a spectrum of immune-related adverse events (irAEs). Rapid recognition and timely treatment of these patients is essential for improved outcomes. Methods: We conducted a systematic review of English-language articles in MEDLINE, EMBASE, Web of Science, PubMed, and Cochrane CENTRAL databases on patients with head and neck cancer treated with immune checkpoint inhibitors who developed treatment-related adverse events. Results: Of 1715 unique citations, 11 studies met inclusion criteria. Eight patients with serious irAEs were reported from case reports and case series. Overall, 46 treatment-related AEs were identified from the pooled 791 patients with at least 12 having potential relevance to irAEs. The most frequent AEs observed in patients receiving PD-1 inhibitors involved the endocrine, cutaneous, and gastrointestinal systems. Conclusions: Characterizing irAEs in longitudinal studies is needed for developing strategies for their prompt recognition and management.

Original languageEnglish (US)
Pages (from-to)4036-4050
Number of pages15
JournalHead and Neck
Volume41
Issue number11
DOIs
StatePublished - Nov 1 2019

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review'. Together they form a unique fingerprint.

Cite this